SIRT1 (Sirtuin 1) is an NAD+-dependent class III histone deacetylase (HDAC) of approximately 81 kDa that functions as a master regulator of cellular stress responses, metabolism, aging, and longevity. As a highly conserved NAD+-dependent deacetylase, SIRT1 removes acetyl groups from lysine residues on histones and numerous non-histone proteins, thereby modulating gene expression, protein function, and cellular homeostasis. In the nervous system, SIRT1 plays critical roles in neuronal survival, synaptic plasticity, memory formation, and has emerged as a significant protective factor in Alzheimer's disease, Parkinson's disease, Huntington's disease, and other neurodegenerative disorders[1][2].
SIRT1 belongs to the sirtuin family of proteins, which are evolutionarily conserved from yeast to humans and require NAD+ as an essential cofactor. This NAD+ dependence links SIRT1 activity directly to cellular energy status and metabolic state, making it a unique therapeutic target at the intersection of metabolism and neurodegeneration.
| SIRT1 (Sirtuin 1) | |
|---|---|
| Protein Name | SIRT1 (NAD-dependent deacetylase Sirtuin-1) |
| Gene Symbol | SIRT1 |
| UniProt ID | Q96EB6 |
| PDB Structures | 4IG0, 1ZC4, 5B2R, 5Y3F |
| Molecular Weight | 81 kDa |
| Amino Acids | 747 |
| Subcellular Localization | Nucleus, Cytoplasm (shuttles between compartments) |
| Protein Family | Sirtuin family (Class III HDACs) |
| Brain Expression | High in [cortex](/brain-regions/cortex), [hippocampus](/brain-regions/hippocampus), cerebellum, hypothalamus |
SIRT1 possesses a modular structure optimized for its NAD+-dependent deacetylase activity[3]:
N-terminal region: Contains a flexible regulatory domain with nuclear localization signals (NLS) and binding sites for various activators and inhibitors. This region also contains sites for post-translational modifications that regulate SIRT1 activity.
Catalytic core: The conserved Rossmann fold (~275 amino acids) comprises the enzymatic center, containing the NAD+-binding pocket and the substrate-binding groove. The active site features a conserved catalytic triad (His-363, Asn-395, His-402 in human SIRT1) that facilitates the deacetylation reaction.
C-terminal region: A regulatory element that auto-inhibits catalytic activity through intramolecular interactions. This region can be cleaved by caspases, generating a truncated active form.
The unique NAD+ requirement of SIRT1 distinguishes it from classical HDACs:
SIRT1 activity is regulated by multiple post-translational mechanisms:
SIRT1 functions as a major epigenetic regulator in the brain[@albani2014]:
SIRT1 integrates metabolic signals to regulate cellular energy homeostasis[4]:
SIRT1 is a central mediator of cellular stress responses:
SIRT1 has potent anti-inflammatory effects[5]:
SIRT1 promotes autophagy through deacetylation of autophagy-related proteins[6]:
SIRT1 is essential for cognitive function:
SIRT1 protects against amyloid-beta (Aβ) pathology through multiple mechanisms[7]:
SIRT1 directly modulates tau pathology[8]:
SIRT1 counteracts neuroinflammation in AD[9]:
SIRT1 supports mitochondrial health in AD[10]:
SIRT1 protects the vulnerable dopaminergic neurons that degenerate in PD:
SIRT1 mitigates oxidative stress, a major pathogenic factor in PD:
SIRT1 may interact with LRRK2 pathogenic mechanisms:
SIRT1 dysfunction contributes to Huntington's disease pathogenesis:
SIRT1 is a major therapeutic target for neurodegenerative diseases[11][12]:
| Agent | Mechanism | Clinical Status | Notes |
|---|---|---|---|
| Resveratrol | Direct SIRT1 activation | Phase II/III | Natural polyphenol, limited bioavailability |
| SRT1720 | Direct SIRT1 activation | Preclinical | 1000x more potent than resveratrol |
| SRT2104 | Direct SIRT1 activation | Phase I | Improved pharmacokinetic properties |
| SRT3025 | Direct SIRT1 activation | Preclinical | Brain-penetrant |
| STAC-3 | SIRT1 activation | Preclinical | Novel synthetic activator |
| Agent | Mechanism | Clinical Status | Notes |
|---|---|---|---|
| NMN (Nicotinamide mononucleotide) | NAD+ precursor | Phase I/II | Directly increases SIRT1 activity |
| NR (Nicotinamide riboside) | NAD+ precursor | Phase I/II | Excellent brain penetration |
| NAMPT activators | Boost NAD+ synthesis | Research | Enhance endogenous NAD+ production |
SIRT1 research employs diverse experimental approaches:
Key techniques include deacetylation assays, NAD+ measurement, chromatin immunoprecipitation (ChIP), and live-cell imaging of autophagy.
Haigis MC, Sinclair DA. Mammalian sirtuins: biological networks and disease. Cell. 2010. ↩︎
Kim D, Nguyen MD, Dobbin MM, et al. SIRT1 deacetylase protects against neuronal degeneration in models of Alzheimer's disease and Huntington's disease. Nature Reviews Neuroscience. 2007. ↩︎
Bonkowski MS, Sinclair DA. Slowing aging by targeting NAD+ metabolism. Nature Reviews Drug Discovery. 2014. ↩︎
Houtkooper RH, Auwerx J. Exploring the therapeutic potential of NAD+ boosting agents. Nature Reviews Drug Discovery. 2012. ↩︎
Donner NC, Tuesta L, Botta L, et al. SIRT1 in neuroinflammation and neurodegenerative diseases. Frontiers in Aging Neuroscience. 2020. ↩︎
Pezzulo G, Xu J, Wunder KA, et al. An endogenous NAD-dependent deacetylase that regulates mitochondrial dynamics. Cell Metabolism. 2013. ↩︎
Qin W, Yang T, Ho L, et al. Neuronal SIRT1 activation as a novel mechanism underlying the prevention of Alzheimer disease amyloid neuropathology. Journal of Biological Chemistry. 2006. ↩︎
Min SW, Cho SH, Zhou Y, et al. Acetylation of tau inhibits its degradation and contributes to tauopathy. Neuron. 2010. ↩︎
Agrawal R, Tiwari RL, Singh A, et al. SIRT1 regulates autophagy in microglia and protects against neuroinflammation. GLIA. 2018. ↩︎
Jahr B, Ernst L, Wenzel F, et al. NAD+ metabolism in brain aging and neurodegeneration. Acta Neuropathologica. 2018. ↩︎
Baur JA, Pearson KJ, Price NL, et al. Resveratrol improves health and survival of mice on a high-calorie diet. Nature. 2006. ↩︎
Howitz KT, Bitterman KJ, Cohen HY, et al. Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature. 2003. ↩︎